Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2005

View Archived Issues

Clinical study of Sativex in patients with peripheral neuropathic pain

Tolerability and pharmacokinetics of LY-450139 assessed in healthy volunteers

Jazz Pharmaceuticals completes acquisition of Orphan Medical

Pre-NDA meeting for AzaSite

License and equity agreement for Neovacs' TNF-alpha kinoid

Emergent BioSolutions acquires Microscience

Pfizer: no evidence of increased risk of blindness among Viagra patients

ChemGenex and Stragen to accelerate development of Ceflatonin

NeuroSolutions and Sosei collaboration identifies neuropathic pain compound

Genaera reaches SPA agreement on phase III trials for Evizon

Phase III endocarditis and bacteremia trial of Cubicin meets primary endpoints

GeneMax receives primary vaccine candidate for oncology

IND submission for MS drug laquinimod

Preclinical neuroprotective effects of iptakalim suggest potential efficacy in Parkinson's disease

Preclinical and clinical data on CJC-1295 reported

SJ-8026 possesses antiangiogenic and antitumor apoptotic activities

454's ultra-deep sequencing able to detect low levels of drug-resistant HIV

Novel diagnostic agents reported in recent patent literature

New data from the IMPACT studies support the use of infliximab in psoriatic arthritis

Update on the benefits of adalimumab in arthritis

Therapeutic agents for fibrotic disorders reported by Nihon University

Telmisartan shows promise in the management of early morning blood pressure surge

Insulin glargine improves the benefits of early antiglycemic therapy in type 2 diabetes

Compounds for lipoprotein disorders, obesity, etc. in early development

Xyrem receives positive opinion for cataplexy in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...